On Friday, Opus Genetics Inc (NASDAQ: IRD) opened higher 2.52% from the last session, before settling in for the closing price of $1.19. Price fluctuations for IRD have ranged from $0.65 to $1.75 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 24.32%. Company’s average yearly earnings per share was noted 73.49% at the time writing. With a float of $22.61 million, this company’s outstanding shares have now reached $59.91 million.
Opus Genetics Inc (IRD) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Opus Genetics Inc is 59.23%, while institutional ownership is 23.08%. The most recent insider transaction that took place on Dec 26 ’24, was worth 97,600. In this transaction Chief Executive Officer of this company bought 100,000 shares at a rate of $0.98, taking the stock ownership to the 599,150 shares. Before that another transaction happened on Nov 21 ’24, when Company’s President bought 10,000 for $0.98, making the entire transaction worth $9,834. This insider now owns 342,800 shares in total.
Opus Genetics Inc (IRD) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.29 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.23) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 73.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 44.13% during the next five years compared to 24.32% growth over the previous five years of trading.
Opus Genetics Inc (NASDAQ: IRD) Trading Performance Indicators
Check out the current performance indicators for Opus Genetics Inc (IRD). In the past quarter, the stock posted a quick ratio of 1.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.76, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Opus Genetics Inc (IRD)
Looking closely at Opus Genetics Inc (NASDAQ: IRD), its last 5-days average volume was 0.19 million, which is a drop from its year-to-date volume of 0.53 million. As of the previous 9 days, the stock’s Stochastic %D was 60.78%.
During the past 100 days, Opus Genetics Inc’s (IRD) raw stochastic average was set at 51.82%, which indicates a significant decrease from 78.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0708 in the past 14 days, which was lower than the 0.0752 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1009, while its 200-day Moving Average is $1.0513. However, in the short run, Opus Genetics Inc’s stock first resistance to watch stands at $1.2436. Second resistance stands at $1.2672. The third major resistance level sits at $1.3040. If the price goes on to break the first support level at $1.1832, it is likely to go to the next support level at $1.1464. Should the price break the second support level, the third support level stands at $1.1228.
Opus Genetics Inc (NASDAQ: IRD) Key Stats
There are currently 59,908K shares outstanding in the company with a market cap of 73.09 million. Presently, the company’s annual sales total 10,990 K according to its annual income of -57,530 K. Last quarter, the company’s sales amounted to 2,880 K and its income totaled -7,420 K.
